A TMCx company has raised money in Houston, UH's online program named best in the nation, and more Houston innovation news. Courtesy of TMCx

Houston's innovation ecosystem has seen a busy January so far — the city has claimed a unicorn in High Radius, The Ion has named a series of new execs, and so much more.

Given this influx of news, you might've missed some other Houston innovation headlines, like UH being recognized for its online master's program, recent fundings, and Texas being named a state for female entrepreneurs. Here's a few short stories to catch you up.

Texas Halo Fund invests in TMCx company

Photo via kegg.tech

A medical device company that focuses on keeping its female users in control of their fertility health just received an investment from a Houston venture capital firm.

Texas Halo Fund invested $200K in kegg, a San Francisco-based startup that participated in the Texas Medical Center's TMCx09 cohort. The device is an easy-to-use fertility tracker that easily analyzes cervical fluid to help detect a woman's ovulation up to 7 days in advance. Kegg pairs with a smartphone app to inform and track the user's fertility.

"kegg appeals to us for many reasons. We believe the FemTech space is growing and that women are looking take charge of their fertility. There is an increased desire to have insights into one's health and understanding trends in fertility is a natural progression, says Kyra Doolan, managing Director at Texas Halo Fund, in a news release.

"We've been impressed by the company's CEO Kristina Cahojova and how far she's taken the company with a limited budget. We look forward to seeing the product hit the consumer market."

University of Houston recognized for online graduate program

Photo courtesy of University of Houston

The University of Houston's College of Education's online master's degree programs have been recognized by U.S. News & World Report as among the top in the nation.

The college ranked No. 8 for its program in a ranking that factored in student engagement, technology tools, surveys of deans, faculty credentials, and student excellence, according to a news release from UH.

"Our faculty and staff strive to give students a top-notch experience online," says Bob McPherson, dean of the UH College of Education, in the news release. "We work to emphasize high-quality instruction and support while allowing students the flexibility and personalization of an online learning environment."

UH's program tied for No. 8 with six other schools, but it's still a huge step up from last year's ranking of No. 19.

Texas ranks No. 5 for female entrepreneurs

 Getty Images

According to a new ranking from Fit Small Business, Texas is the fifth best state for female entrepreneurs. The Lone Star State is holding strong in the top tier but slipped from its No. 1 ranking last year.

"High start-up growth, no corporate income tax, and a moderate cost of living are all big pluses for the state, but how does it do regarding a friendly women's business and safety climate?" the report reads. "Well, sort of 'middle-of-the-road,' by the numbers we sourced."

Each state was evaluated by four equally weighted factors: its general business climate and opportunity, the number of female-owned businesses, economic and financial health, and safety and well-being for women. Texas's startup climate and opportunity, which was weighted by 35 percent in the study, was ranked No. 4. When it came to economic and financial health, weighted at 15 percent, Texas also snagged the No. 4 spot.

Rice Business Plan Competition startup raises $1.1 million

Photo via resonado.com

Resonado, the runner-up at the 2019 Rice Business Plan Competition, has raised $1.1 million in funding for its thinner, better-sounding speaker system technology.

The company was founded by four University of Notre Dame University classmates — Brian Cho, Christian Femrite, Erik Perez-Perez, and Peter Moeckel.

Rice University's OWL Investment contributed to the round.

Fannin Innovation Studio makes strategic hire

Praveen Kudithipudi

Photo via fannininnovation.com

Praveen Kudithipudi has been named as director of business development at Houston-based Fannin Innovation Studio. He supports the licensing of Fannin's portfolio technologies as well as collaborations with pharmaceutical companies and academic partners.

"I am excited to have a wonderful opportunity to work at Fannin," says Kudithipudi in the news release. "Fannin builds successful life sciences startups while helping to catalyze the formation of a thriving and sustainable life sciences entrepreneurship ecosystem in Houston. The opportunity to lead licensing, diligence, and collaboration efforts with academic institutions and biotechnology companies here in Houston is truly a unique opportunity."

Kudithipudi received his medical degree in India and specialized in neuroscience in the United Kingdom. He received his MBA from New York University. Prior to this role, he worked in banking, venture capital, and investments in New York.

"We are excited to have someone with the range of experiences and caliber of Praveen on the team," says Atul Varadhachary, Fannin managing partner, in the release. "In our business, we look for high potential technologies at an early stage. Having someone with both a medical background and Wall Street know-how is invaluable to us as we review opportunities and reach out to prospective development partners."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.